文献分析结果 http://www.gopubmed.org/web/gopubmed/1?WEB0cjms930ump6wI10I1xI0 Helicobacter pylori and precancerous lesion 76 documents semantically analyzed top author statistics Top Years Publications 2007 9 2006 7 2003 7 2002 7 2001 7 2008 6 1997 6 2009 5 2000 5 2010 3 2004 3 2005 2 1998 2 1995 2 1999 1 1996 1 1994 1 1992 1 1991 1 1 2 Top Countries Publications Japan 18 USA 13 China 9 South Korea 5 Italy 5 Germany 5 Peru 3 Bosnia and Herzegovina 2 Taiwan 2 United Kingdom 2 Australia 1 Costa Rica 1 Russia 1 France 1 Sweden 1 Colombia 1 Finland 1 Hong Kong 1 Portugal 1 Iceland 1 1 2 1 2 3 Top Cities Publications Seoul 3 Changsha 3 Beijing 3 Padua 3 Nagoya 3 New Orleans 3 ōita 3 Tucson 3 Lima 3 Daegu 2 Shenyang 2 Sarajevo 2 Tbingen 2 Cambridge, USA 2 Fukuoka 2 Kushiro 1 Wakayama 1 Melbourne 1 ōtsu 1 San Jos 1 1 2 3 1 2 3 Top Journals Publications J Clin Pathol 4 Cancer Epidem Biomar 3 World J Gastroentero 3 J Clin Gastroenterol 3 Cancer 3 Int J Cancer 2 Dig Dis Sci 2 Zhonghua Yi Xue Za Zhi 2 Zhong Nan Da Xue Xue Bao Yi Xue Ban 2 Bosn J Basic Med Sci 2 Am J Gastroenterol 2 Praxis (bern 1994) 2 Gut 2 Digest Dis Sci 2 Nippon Rinsho 2 Scand J Gastroenterol Suppl 2 Unknown Journal 1 Histopathology 1 J Pathol 1 J Gastroenterol Hepatol 1 1 2 3 1 2 3 ... 33 Top Terms Publications Helicobacter pylori 74 Humans 70 Stomach Neoplasms 68 Helicobacter 66 Helicobacter Infections 63 Gastritis 52 Precancerous Conditions 51 Patients 47 gut development 45 Intestines 45 Metaplasia 44 Gastric Mucosa 40 Middle Aged 37 Mucous Membrane 34 Aged 30 Adenocarcinoma 28 Gastritis, Atrophic 27 Biopsy 24 Adult 21 Diagnosis 19 1 2 3 ... 33 1 2 3 ... 20 Top Authors Publications Tatematsu M 3 Correa P 3 Kodama M 3 Fujioka T 3 Sampliner R 3 Len-Bara R 3 Wang F 2 Tsukamoto T 2 Mizoshita T 2 Yuan Y 2 Sun L 2 Gornjakovi? S 2 Vukobrat-Bijedi? Z 2 Radovi? S 2 Husi?-Selimovi? A 2 Kohgo Y 2 Watari J 2 Fontham E 2 El-Zimaity H 2 Graham D 2 1 2 3 ... 20 最新研究进展 Int J Cancer. 2010 Mar 15;126(6):1467-73. Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. Yanaoka K , Oka M , Yoshimura N , Deguchi H , Mukoubayashi C , Enomoto S , Maekita T , Inoue I , Ueda K , Utsunomiya H , Iguchi M , Tamai H , Fujishiro M , Nakamura Y , Tsukamoto T , Inada K , Takeshita T , Ichinose M . Department of Gastroenterology, School of Medicine, Wakayama Medical University, Wakayama City, Wakayama 641-0012, Japan. Abstract The present study investigated the preventive effects of etodolac, a selective cyclo-oxygenase (COX)-2 inhibitor, on metachronous cancer development after endoscopic resection of early gastric cancer. Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions. Nonrandomized etodolac treatment (300 mg/day) was administered to 26 patients (Group A), while the remaining 21 patients were untreated (Group B). No significant differences in age, sex distribution, lifestyle factors or extent of metaplastic gastritis at baseline were identified between groups. Patients were followed for metachronous cancer development with endoscopy every 6-12 months for up to 5 years. Mean (standard deviation) follow-up period was 4.2 (0.9) years. In Group B, 5 cancers developed (incidence rate = 6,266/100,000 person-years), significantly more than the 1 cancer in Group A (incidence rate = 898/100,000 person-years; p 0.05). Long-term etodolac treatment did not influence the extent of metaplastic gastritis as revealed by endoscopic findings or by serum PG levels, but effectively reduced metachronous cancer development in patients with extensive metaplastic gastritis. These results strongly suggest that chemoprevention of cancer in the metaplastic stomach is possible by controlling COX-2 expression. PMID: 19711347 Publication Types, MeSH Terms, Substances Publication Types: Clinical Trial Research Support, Non-U.S. Gov't MeSH Terms: Aged Cyclooxygenase 2 Inhibitors/therapeutic use* Etodolac/therapeutic use* Female Follow-Up Studies Gastritis/complications Gastritis/diagnosis Gastritis/prevention control* Helicobacter pylori/drug effects Humans Kaplan-Meiers Estimate Male Middle Aged Precancerous Conditions/complications Precancerous Conditions/microbiology Precancerous Conditions/prevention control Stomach/drug effects Stomach/pathology Stomach/surgery Stomach Neoplasms/complications Stomach Neoplasms/prevention control* Stomach Neoplasms/surgery Treatment Outcome Substances: Cyclooxygenase 2 Inhibitors Etodolac LinkOut - more resources Full Text Sources: John Wiley Sons, Inc. EBSCO OhioLINK Electronic Journal Center Swets Information Services Other Literature Sources: Evaluations and comments from leading biologists - Faculty of 1000 Biology Medical: Stomach Cancer - MedlinePlus Health Information Libraries: LinkOut Holdings Related citations 相关文献 Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Magari H, Shimizu Y, Inada K, Enomoto S, Tomeki T, Yanaoka K, Tamai H, Arii K, Nakata H, Oka M, et al. Biochem Biophys Res Commun. 2005 Aug 26; 334(2):606-12. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, et al. Int J Cancer. 2009 Dec 1; 125(11):2697-703. Cancer precursor lesions in intact stomach Helicobacter pylori gastritis and in resected stomach gastritis. Cancer precursor lesions in intact stomach Helicobacter pylori gastritis and in resected stomach gastritis. Giuliani A, Spada S, Corona M, Demoro M, Di Bari M, Ricciardulli T, Galati G, Caporale A, Tocchi A, Angelico F. J Exp Clin Cancer Res. 2003 Sep; 22(3):371-8. Review Helicobacter pylori eradication for the prevention of gastric cancer. Review Helicobacter pylori eradication for the prevention of gastric cancer. Kuipers EJ, Sipponen P. Helicobacter. 2006 Oct; 11 Suppl 1:52-7. Review Review Asaka M. Gan To Kagaku Ryoho. 2009 Aug; 36(8):1223-7. See reviews... See all...